(44) Garsi, J. B.; Aguiar, P. M.; Berger, G.; Maris, T.; Hanessian, S. Pseudodiproline (Pro-Cyp) Oligomers Fold into Helical Polyproline Type Secondary Structures. J. Org. Chem. 2023, 89, 4283-4293.
(43) Greif, C. E.; Mertens, R. T.; Berger, G.; Parkin, S.; Awuah, S. G. An Anti-Glioblastoma Gold(I)–NHC Complex Distorts Mitochondrial Morphology and Bioenergetics to Induce Tumor Growth Inhibition. RSC Chem. Biol. 2023, 4, 592–599.
(42) Kumar, S.; Body, C.; Leyssens, T.; Hecke, K. Van; Berger, G.; Lee, A. Van Der; Laurencin, D.; Richeter, S.; Meyer, F. Halogen-Bonded Thiophene Derivatives Prepared by Solution and/ or Mechanochemical Synthesis. Evidence of N···S Chalcogen Bonds in Homo- and Cocrystals. Cryst. Growth Des. 2023, ASAP.
(41) Sow, I. S.; Gelbcke, M.; Meyer, F.; Vandeput, M.; Marloye, M.; Basov, S.; Van Bael, M. J.; Berger, G.; Robeyns, K.; Hermans, S.; Yang, D.; Fontaine, V.; Dufrasne, F. Synthesis and Biological Activity of Iron(II), Iron(III), Nickel(II), Copper(II) and Zinc(II) Complexes of Aliphatic Hydroxamic Acids. J. Coord. Chem. 2023, 76 (1), 76-105.
(40) Jimenez-macias, J. L.; Lee, Y.; Miller, E.; Finkelberg, T.; Zdioruk, M.; Berger, G.; Farquhar, C. E.; Nowicki, M. O.; Cho, C.; Fedeles, B. I.; Loas, A.; Pentelute, B. L. A Pt(IV)-Conjugated Brain Penetrant Macrocyclic Peptide Shows Pre-Clinical Efficacy in Glioblastoma, J. Control. Release 2022, 352, 623–636.
(39) Berger, G.; Knelson, E.; Nowicki, M.O.; Jimenez, J.L.; Stafford, A.; Mooney, D.J.; Chiocca, A.; Barbie, D.A.; Lawler, S.E. STING activation promotes robust immune response and NK-cell mediated tumor regression in glioblastoma models, Proc. Natl. Acad. Sci. 2022, 119 (28), e2111003119.
(38) Arnold, J. E.; Morency, M.; Chartrand, D.; Maris, T.; Berger, G.; Day, G. M.; Hanessian, S.; Wuest, J. D. Surprising Chemistry of 6‑Azidotetrazolo[5,1‑a]Phthalazine: What a Purported Natural Product Reveals about the Polymorphism of Explosives, J. Org. Chem. 2022, 87, 6680-6694.
(37) Marloye, M.; Mathieu, V.; Debaille, V.; Nowicki, M. O.; Meyer, F.; Lawler, S. E.; Dufrasne, F.; Berger, G. Directed self-assembly of ruthenium and osmium nanoparticles display potent in vivo anticancer profile by interfering with metabolic activity, Inorg. Chem. Front. 2022, 9, 2594-2607.
(36) Tyler Mertens, R.; Greif, C. E.; Coogle, J. T.; Berger, G.; Parkin, S.; Watson, M. D.; Awuah, S. G. Stable Au(I) Catalysts for Oxidant-Free C-H Functionalization with Iodoarenes. J. Catal. 2022, in press.
(35) Schawe, L.; Raude, B.; Carstens, J. C.; Hinterseher, I.; Hein, R. D.; Omran, S.; Berger, G.; Hering, N. A.; Buerger, M.; Greiner, A.; Frese, J. P. Effect of Revascularization on Intramuscular Vascular Endothelial Growth Factor Levels in Peripheral Arterial Disease, Biomolecules 2022, 10(2), 471-481.
(34) Berger, G.;* Hocine, S.;* Houk, K.; Hanessian, S. Catalytic properties of 4,5-bridged proline methano- and ethanologues in the Hajos-Parrish intramolecular aldol reaction, Org. Chem. Front., 2022, 9, 649-659. *Co-first author
(33) Marloye, M.; Dufrasne, F.; Meyer, F.; Berger, G. Synthesis, structure and anticancer properties of new biotin‑ and morpholine‑functionalized ruthenium and osmium half‑sandwich complexes, J. Biol. Inorg. Chem. 2021, 26, 535-549.
(32) Berger, G.; Wach, A.; Sá, J.; Szlachetko, J. Reduction mechanism of anticancer osmium(VI) complexes revealed by atomic telemetry and theoretical calculations, Inorg. Chem. 2021, 60, 9, 6663-6671.
(31) Berger, G.; Frangville, P.; Meyer F. Halogen bonding for molecular recognition: new developments in materials and biological sciences, Chem. Commun. 2020, 56, 4970-4981.
(30) Hocine S.; Berger, G.; Hanessian, S. Design and synthesis of backbone-fused, conformationally locked bridged morpholine-proline chimeras, J. Org. Chem. 2020, 85, 6, 4237-4247.
(29) Marloye, M.; Lawler, S.E.; Berger, G. Current patent status of STING agonists for cancer immunotherapy, Pharm. Pat. Anal. 2019, 8, 87-90.
(28) Yang D.; Guy Vandenbussche G.; Vertommenand D.; Wohlkönig A.; Berger G.; Khan M.S.; Zeng S.; Soumillion P.; Fontaine V. Methyl arachidonyl fluorophosphonate inhibits Mycobacterium tuberculosis TesA thioesterase, accepted manuscript.
(27) Kim, J.H.; Mertens, R.T.; Agarwal, A.; Parkin, S.; Berger, G.; Awuah, S.G. Direct intramolecular carbon(sp2)-nitrogen(sp2) reductive elimination from gold(III), Dalton Trans., 2019, 48, 6273-6282.
(26) Berger, G.; Marloye M.; Lawler S.E. Pharmacological modulation of the STING pathway for cancer immunotherapy, Trends Mol. Med. 2019, 25(5), 412-427, Front Cover.
(25) Berger, G.; Lawler S.E. Novel non-nucleotidic STING agonists for cancer immunotherapy, invited Editorial, Future Med. Chem. 2018, 10(24), 2767-2769.
(24) Berger, G.; Soubhye, J.; Robijns, K.; Meyer, F. Crystal packing and theoretical analysis of halogen- and hydrogen-bonded hydrazones from pharmaceuticals, Acta Cryst. 2018, B74, 618-627.
(23) Vernekar A.; Berger G.; Czapar A.; Wang D.I.; Steinmetz N.; Lippard S. J. J. Am. Chem. Soc. 2018, J. Am. Chem. Soc. 2018,140, 12, 4279-4287.
(22) Berger, G.; Grauwet, K.; Zhang, H.; Hussey, A. M.; Nowicki, M. O.; Wang, D. I.; Chiocca, E. A.; Lawler, S. E.; Lippard, S. J. Cancer Lett. 2018, 416, 138–148.
(21) Chen, B.; Berger, G; Hanessian, S. Eur. J. Org. Chem. 2017, 2631–2636.
(20) Chikh Alard, I.; Soubhye, J.; Berger, G.; Gelbcke, M.; Spassov, S.; Amighi, K.; Goole, J.; Meyer, F. Polym. Chem. 2017, 8, 2450–2456. Front Cover.
(19) Berger, G.; Chab-Majdalani, I.; Hanessian, S. Isr. J. Chem. 2017, 57 (3–4), 292–302.
(18) Marloye, M.; Berger, G.; Gelbcke, M.; Dufrasne, F. Futur Med. Chem. 2016, 8 (18), 2263–2286.
(17) Levet, V.; Rosière, R.; Merlos, R.; Fusaro, L.; Berger, G.; Amighi, K.; Wauthoz, N. Int. J. Pharm. 2016, 515 (1–2), 209–220.
(16) Aldib, I.; Gelbcke, M.; Soubhye, J.; Prévost, M.; Furtmüller, P. G.; Obinger, C.; Elfving, B.; Alard, I. C.; Roos, G.; Delporte, C.; Berger, G.; Dufour, D.; Zouaoui Boudjeltia, K.; Nève, J.; Dufrasne, F.; Van Antwerpen, P. Eur. J. Med. Chem. 2016, 123, 746–762.
(15) Chattopadhyay, A. K.; Berger, G.; Hanessian, S. J. Org. Chem. 2016, 81, 5074−5086.
(14) Chattopadhyay, A. K.; Ly, V. L.; Jakkepally, S.; Berger, G.; Hanessian, S. Angew. Chemie Int. Ed. 2016, 55, 2577–2581.
(13) Sá, J.; Czapla-Masztafiak, J.; Lipiec, E.; Kayser, Y.; Fernandes, D. L. A.; Szlachetko, J.; Dufrasne, F.; Berger, G. Analyst 2016, 141 (4), 1226–1232.
(12) Berger, G.; Robeyns, K.; Soubhye, J.; Wintjens, R.; Meyer, F. CrystEngComm 2016, 18, 683–690.
(11) Berger, G.; Vilchis-Reyes, M.; Hanessian, S. Angew. Chemie Int. Ed. 2015, 54, 13268–13272.
(10) Sá, J.; Czapla-Masztafiak, J.; Lipiec, E.; Kayser, Y.; Kwiatek, W.; Wood, B.; Deacon, G. B.; Berger, G.; Dufrasne, F.; Fernandes, D. L. A.; Szlachetko, J. Drug Discov. Today Technol. 2015, 16, 1–6.
(9) Berger, G.; Wintjens, R.; Meyer, F. In Targets in Heterocyclic Systems; Attanasi, O. A., Noto, R., Spinelli, D., Eds.; Società Chimica Italiana: Roma, 2014; pp 29–47.
(8) Berger, G.; Fusaro, L.; Luhmer, M.; Czapla-Masztafiak, J.; Lipiec, E.; Szlachetko, J.; Kayser, Y.; Fernandes, D. L. a.; Sá, J.; Dufrasne, F.; Bombard, S. J. Biol. Inorg. Chem. 2015, 20 (5), 841–853.
(7) Berger, G.; Soubhye, J.; Meyer, F. Polym. Chem. 2015, 6 (19), 3559–3580. Selected for back cover.
(6) Berger, G.; Fusaro, L.; Luhmer, M.; van der Lee, A.; Crousse, B.; Meyer, F. Tetrahedron Lett. 2014, 55 (46), 6339–6342.
(5) Berger, G.; Leclercqz, H.; Derenne, A.; Gelbcke, M.; Goormaghtigh, E.; Nève, J.; Mathieu, V.; Dufrasne, F. Bioorg. Med. Chem. 2014, 22 (13), 3527–3536.
(4) Berger, G.; Soubhye, J.; van der Lee, A.; Vande Velde, C.; Wintjens, R.; Dubois, P.; Clément, S.; Meyer, F. ChemPlusChem 2014, 79 (4), 552–558.
(3) Berger, G. Comput. Theor. Chem. 2013, 1010, 11–18.
(2) Berger, G.; Gelbcke, M.; Cauët, E.; Luhmer, M.; Nève, J.; Dufrasne, F. Tetrahedron Lett. 2013, 54 (6), 545–548.
(1) Berger, G.; Gasper, R.; Lamoral-theys, D.; Wellner, A.; Gelbcke, M.; Gust, R.; Nève, J.; Kiss, R.; Goormaghtigh, E.; Dufrasne, F. Fourier transform infrared spectroscopy to monitor the cellular impact of newly synthesized platinum derivatives, Int. J. Oncol. 2010, 37, 679–686.
* * *
Active participation in national and international conferences
(17) “Metal-Based Anticancer Therapeutics: Short Stories”, Invited talk at La Sorbonne and Ecole Nationale Supérieure de Chimie ParisTech, Paris – France, March 2022.
(16) “Short Stories in Medicinal Chemistry”, MedChem2021 – Invited Plenary at the Annual One-Day Meeting on Medicinal Chemistry of SRC & KVCV – Liège – Belgium, November 2021.
(16) “STING activation promotes robust immune response and tumor regression in glioblastoma models” – 26th Annual Meeting of the Society for Neuro-Oncology, Boston, November 2021.
(14) “Modern computational tools in catalysis, drug synthesis and design: recent examples from my research” Oral presentation, European Workshop in Drug Synthesis – Certosa di Pontignano, Siena (Italy), May 2018
(13) “Explorations of Metal-Based Anticancer Therapeutics”, Group Seminar (H. Wennemers Lab), ETH Zürich, November 2017.
(12) “Explorations of Metal-Based Anticancer Therapeutics”, Invited Lecture, University of Tabasco – Mexico, October 2017.
(11) “Explorations of Metal-Based Anticancer Therapeutics”, Award Talk, Journées Franco-Belges de Pharmacochimie, Spa – Belgium, September 2017
(10) “Structural Properties of 4,5-Methanoprolines and their Oligomers: An Unprecedented Crystalline PPII-type Helical Tetramer”, Oral presentation, Tenth European Workshop in Drug Design – Certosa di Pontignano, Siena (Italy), May 2015
(9) “Bifunctional Cooperative Catalysis Toward Tertiary β-Ketols: A Theoretical Mechanistic Study”, Poster, Tenth European Workshop in Drug Design – Certosa di Pontignano, Siena (Italy), May 2015
(8) “4,5-Methanoprolines, bifunctional-catalyzed aldol reactions and the chemistry of benzodiazidodiazines: from the bench to the theory”, Oral presentation, Year-End Symposium (Hanessian Group), Université de Montréal – Montreal, November 2014
(7) “Synthesis and in vitro characterization of anticancer platinum(II) coordinates: NCI Compare and FTIR spectroscopy for drug candidate profiling”, Poster, International Congress on Bioinorganic Chemistry – Grenoble, July 2013
(6) Vicinal Diamines through N-Activated Chiral Aziridines: Synthesis and Conceptual Density Functional Theory Study”, Poster, 13th Belgian Organic Synthesis Symposium – Leuven, July 2012
(5)“Regioselective Opening of N-Activated Aziridines: A Quantum Chemical Study”, Poster, Journée Scientifique de la Société Royale de Chimie – Louvain-La-Neuve, October 2012
(4) “Chiral Diamines through the Regioselective Opening of Nitrogen-Activated Aziridines: Synthesis and Quantum Chemical Study”, Oral presentation, PhD Day – Bruxelles (ULB), October 2012
(3) “Insight into the Structure-Activity Relationships of Platinum(II) Anticancer Coordinates”, Poster, PhD Day – Bruxelles (ULB), October 2012
(2) “Synthesis and In Vitro Anticancer Properties of Platinum Derivatives” Oral presentation, 25èmes Journées franco-belges de pharmacochimie – Liège, May 2011
(1) “Fourier Transform Infrared (FTIR) Spectroscopy to Monitor the Cellular Impact of Newly Synthesized Platinum Derivatives”, Oral presentation, PhD Day – Mons, May 2010
* * *
LMTC 